Degludec is a long-acting basal insulin (T1/2 = 25 h) which mechanism of protraction is multihexamer formation in the subcutaneous injection depot
70 HP 130 BPC-157 Pentadecapeptide Cytoprotection ALIASES BPC157, Body Protection Compound 157, PL 14736, pentadecapeptide CLASS Synthetic 15-amino-acid peptide gastric-origin fragment FORMULA C62H98N16O22 SEQUENCE Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val HALF-LIFE ~4 hours (rat, intraperitoneal) ROUTES Subcutaneous Intraperitoneal Oral (animal studies) MECHANISM OF ACTION Synthetic 15-amino-acid fragment of a gastric protective protein
Evidence-Supported Indications Adults with BMI 35 kg/m, or BMI 27 with at least one or more weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea Type 2 Diabetes: Adults requiring improved glycemic control this remains the foundation of the drug class and where the longest safety record exists Cardiovascular Risk Reduction: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease Metabolic Syndrome Presentations: Patients with non-alcoholic fatty liver disease, polycystic ovarian syndrome, and insulin resistance syndromes Binge Eating Disorder (BED) Emerging Data: Emerging evidence suggests GLP-1 medications may reduce binge frequency though this data remains preliminary and is discussed in detail below Why It Is Not "Cheating" The genetics of obesity are increasingly well-characterized
Nat Prod Commun (2017) 12:1934578X1701200240
Morselli LL, Nedeltcheva A, Leproult R, Spiegel K, Martino E, Legros JJ, et al
Initial consultation: $0-100 (many offer free consultations) Monthly therapy costs: $175-400 depending on peptides Follow-up appointments: Often included or $25-50 Lab work: Sometimes included, otherwise $150-300 The savings come from eliminated clinic overhead
